Angioedema induced by cardiovascular drugs: new players join old friends
Authors:
Open Access
Abstract
During the last years, two new cardiovascular drug classes, namely inhibitors of DPP IV or neprilysin, have been developed. In both cases, there is clinical evidence for their potential to induce angioedema as known already from blockers of the renin–angiotensin–aldosterone system (RAAS). The majority of angioedema induced by DPP IV inhibitors occurs during concomitant treatment with ACEi and is therefore likely mediated by overactivation of bradykinin type 2 receptors (B2). In striking contrast, the molecular pathways causing angioedema induced by neprilysin inhibitors, that is, sacubitril, are unclear, although a contribution of bradykinin appears likely. Nevertheless, there is no clinical evidence suggesting that inhibition of B2 might relieve the symptoms and/or prevent invasive treatment including coniotomy or tracheotomy in angioedema caused by these drugs. Therefore, the risk of angioedema should always be considered, especially in ambulatory care situations where patients have no rapid access to intensive care.Keywords
This publication has 37 references indexed in Scilit:
- Mast Cells Increase Vascular Permeability by Heparin-Initiated Bradykinin Formation In VivoImmunity, 2011
- Angiotensin I–Converting Enzyme Inhibitors Are Allosteric Enhancers of Kinin B1 and B2 Receptor FunctionHypertension, 2010
- Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated AngioedemaHypertension, 2009
- Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edemaJournal of Allergy and Clinical Immunology, 2007
- Nonallergic angioedema: role of bradykininAllergy, 2007
- Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type IIIThe American Journal of Human Genetics, 2006
- AT 1 -Receptor Antagonism Improves Endothelial Function in Coronary Artery Disease by a Bradykinin/B 2 -Receptor-Dependent MechanismHypertension, 2003
- The angiotensin type II receptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant miceKidney International, 2000
- Fatal Angioedema Associated with Enalapril.Internal Medicine, 1993
- Hereditary and Acquired C1-Inhibitor DeficiencyMedicine, 1992